$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017
[Report Updated: 31-03-2017]

Published by Global Markets Direct: 31 Mar 2017 | 51242 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H1 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 9, 43 and 26 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 14 and 6 molecules, respectively.

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017 [Report Updated: 31-03-2017]

  • Table of Contents

    Table of Contents 2

    Introduction 5

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Overview 6

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Therapeutics Development 7

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Therapeutics Assessment 21

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Companies Involved in Therapeutics Development 29

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drug Profiles 54

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects 228

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products 231

    Ebolavirus Infections (Ebola Hemorrhagic Fever) – Product Development Milestones 232

    Appendix 248

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

51242 | GMDHC9123IDB

Number of Pages

261

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019SummaryGlobal Markets Dire...
25 Nov 2019 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018SummaryGlobal Markets Dire...
13 Mar 2018 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2017SummaryGlobal...
31 Jul 2017 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016SummaryGlobal Markets Dire...
23 Nov 2016 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2016
Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2016SummaryGlobal...
30 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017 [Report Updated: 31-03-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...